Cargando…
Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease
Lipid aldehydes originating from the peroxidation of n-3 and n-6 polyunsaturated fatty acids are increased in hemodialysis (HD) patients, a process already known to promote oxidative stress. However, data are lacking for patients with chronic kidney disease (CKD) before the initiation of HD. We pros...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551374/ https://www.ncbi.nlm.nih.gov/pubmed/32899405 http://dx.doi.org/10.3390/toxins12090567 |
_version_ | 1783593169810620416 |
---|---|
author | Soulage, Christophe O. Pelletier, Caroline C. Florens, Nans Lemoine, Sandrine Dubourg, Laurence Juillard, Laurent Guebre-Egziabher, Fitsum |
author_facet | Soulage, Christophe O. Pelletier, Caroline C. Florens, Nans Lemoine, Sandrine Dubourg, Laurence Juillard, Laurent Guebre-Egziabher, Fitsum |
author_sort | Soulage, Christophe O. |
collection | PubMed |
description | Lipid aldehydes originating from the peroxidation of n-3 and n-6 polyunsaturated fatty acids are increased in hemodialysis (HD) patients, a process already known to promote oxidative stress. However, data are lacking for patients with chronic kidney disease (CKD) before the initiation of HD. We prospectively evaluated the changes of plasma concentrations of two major lipid aldehydes, 4-HHE and 4-HNE, according to the decrease of glomerular filtration rate (GFR) in 40 CKD and 13 non-CKD participants. GFR was measured by inulin or iohexol clearance. Thus, 4-hydroxy-2-nonenal (4-HNE) and 4-hydroxy-2-hexenal (4-HHE) were quantitated in plasma by gas chromatography coupled with mass spectrometry and their covalent adducts on proteins were quantified by immunoblotting. On the one hand, 4-HHE plasma concentration increased from CKD stage I–II to CKD stage IV–V compared to non-CKD patients (4.5-fold higher in CKD IV–V, p < 0.005). On the other hand, 4-HNE concentration only increased in CKD stage IV–V patients (6.2-fold, p < 0.005). The amount of covalent adducts of 4-HHE on plasma protein was 9.5-fold higher in CKD patients than in controls (p < 0.005), while no difference was observed for 4-HNE protein adducts. Plasma concentrations of 4-HNE and 4-HHE are increased in CKD IV–V patients before the initiation of hemodialysis. |
format | Online Article Text |
id | pubmed-7551374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75513742020-10-14 Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease Soulage, Christophe O. Pelletier, Caroline C. Florens, Nans Lemoine, Sandrine Dubourg, Laurence Juillard, Laurent Guebre-Egziabher, Fitsum Toxins (Basel) Article Lipid aldehydes originating from the peroxidation of n-3 and n-6 polyunsaturated fatty acids are increased in hemodialysis (HD) patients, a process already known to promote oxidative stress. However, data are lacking for patients with chronic kidney disease (CKD) before the initiation of HD. We prospectively evaluated the changes of plasma concentrations of two major lipid aldehydes, 4-HHE and 4-HNE, according to the decrease of glomerular filtration rate (GFR) in 40 CKD and 13 non-CKD participants. GFR was measured by inulin or iohexol clearance. Thus, 4-hydroxy-2-nonenal (4-HNE) and 4-hydroxy-2-hexenal (4-HHE) were quantitated in plasma by gas chromatography coupled with mass spectrometry and their covalent adducts on proteins were quantified by immunoblotting. On the one hand, 4-HHE plasma concentration increased from CKD stage I–II to CKD stage IV–V compared to non-CKD patients (4.5-fold higher in CKD IV–V, p < 0.005). On the other hand, 4-HNE concentration only increased in CKD stage IV–V patients (6.2-fold, p < 0.005). The amount of covalent adducts of 4-HHE on plasma protein was 9.5-fold higher in CKD patients than in controls (p < 0.005), while no difference was observed for 4-HNE protein adducts. Plasma concentrations of 4-HNE and 4-HHE are increased in CKD IV–V patients before the initiation of hemodialysis. MDPI 2020-09-03 /pmc/articles/PMC7551374/ /pubmed/32899405 http://dx.doi.org/10.3390/toxins12090567 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Soulage, Christophe O. Pelletier, Caroline C. Florens, Nans Lemoine, Sandrine Dubourg, Laurence Juillard, Laurent Guebre-Egziabher, Fitsum Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease |
title | Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease |
title_full | Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease |
title_fullStr | Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease |
title_full_unstemmed | Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease |
title_short | Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease |
title_sort | two toxic lipid aldehydes, 4-hydroxy-2-hexenal (4-hhe) and 4-hydroxy-2-nonenal (4-hne), accumulate in patients with chronic kidney disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551374/ https://www.ncbi.nlm.nih.gov/pubmed/32899405 http://dx.doi.org/10.3390/toxins12090567 |
work_keys_str_mv | AT soulagechristopheo twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease AT pelletiercarolinec twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease AT florensnans twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease AT lemoinesandrine twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease AT dubourglaurence twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease AT juillardlaurent twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease AT guebreegziabherfitsum twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease |